UberDoc Health Technologies Appoints Lemonaid Health Co-Founder Paul Johnson to Advisory Board and Changes Name to Apptly Health Technologies Corp.

Executive Summary

• Apptly Health Technologies Corp. announced the appointment of Paul Johnson to its Advisory Board.
• The company officially changed its name to Apptly Health Technologies Corp., with shares commencing trading under the existing ticker "APPT" on the Canadian Securities Exchange.
• The company engaged Focus Communications Investor Relations Inc. to manage investor relations and corporate communications for a six-month term.

Key Details

• Paul Johnson appointed to Advisory Board; previously co-founded and served as CEO of Lemonaid Health until its $400 million sale to 23andMe in 2021.
• Name change effective June 23, 2026; new CUSIP: 03790W107; new ISIN: CA03790W1077.
• Common shares will trade under the existing ticker symbol "APPT" on the CSE.
• Engagement of Focus Communications Investor Relations Inc. (FCIR) for investor outreach, shareholder communications, and capital markets advisory services.
• FCIR compensation: C$60,000 over a six-month term commencing June 19, 2026.
• FCIR and its principal own 428,571 Common Shares of the Company.
• No capital consolidation or shareholder action required in connection with the name change.

Notable Quotes

• Dr. Paula M. Muto, Founder and Interim CEO: "Paul did not just build a company, he built a category, and he did it by betting that patients are consumers the moment the system lets them be... Having Mr. Johnson advising us as we scale strengthens our ability to execute with guidance from someone who has already navigated this path successfully."
• Paul Johnson: "Apptly is attacking the access problem from the specialist side, where the cost and the friction concentrate... I am glad to help."